Eli Lilly, the manufacturer of Mounjaro®, has increased the price of all dose strengths in the UK to align with pricing across mainland Europe and other developed markets.
If this change affects your treatment plan, there are clear options available to help you continue your weight loss journey safely and effectively.
Overview
This guide explains:
- Why the price of Mounjaro® has increased
- How this affects your treatment options
- How to continue your weight loss treatment
- When switching to Wegovy® may be appropriate
Why has the price of Mounjaro® changed?
When Mounjaro® first launched in the UK in early 2024, it was priced lower than in other countries to support early access for patients.
Eli Lilly has now adjusted pricing to:
- Align UK pricing with countries such as Germany and the United States
- Support a more consistent global pricing structure
- Contribute fairly to research and development costs
Aligning prices also helps protect UK supply by reducing the risk of medication being exported to higher-priced markets.
What are my options after the price increase?
If the new price affects your budget, you have two main options:
Option 1: Continue with Mounjaro®
You can continue your current Mounjaro® treatment plan without changes:
- Your dosing schedule remains the same
- Your body continues with a medication it is already used to
- No additional clinical adjustments are required unless needed
Option 2: Switch to Wegovy®
Wegovy® (semaglutide) is a clinically effective alternative that may be more cost-effective.
Key points:
- Wegovy® is manufactured by Novo Nordisk and is not affected by the Mounjaro® price change
- Clinical studies show average weight loss of around 15% over 68 weeks
- Your MedExpress clinician will create a safe transition plan based on your current Mounjaro® dose
- Switching is a standard clinical process and can be done safely with guidance
Will switching affect my progress?
A temporary adjustment period is normal when switching medications.
However:
- Both Mounjaro® and Wegovy® are effective GLP-1 treatments
- Your clinician will select the appropriate Wegovy® starting dose
- The goal is to maintain steady progress without interruption
Our commitment to your treatment
We understand that pricing changes can be frustrating. MedExpress is committed to supporting you by providing:
- Transparency about pricing changes
- Flexible options if your treatment needs to change
- Clinical support to ensure safe and effective treatment decisions
Key takeaway
The price of Mounjaro® has increased due to global pricing alignment by the manufacturer.
If this affects you, you can either:
- Continue with Mounjaro® as planned, or
- Switch to Wegovy® with clinical guidance as a cost-effective alternative
If you still need help after reviewing the information above, additional assistance is available.